

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

NOTICE

Notice is hereby given that 24th Annual General Meeting of the members Of Rodec Pharmaceuticals Private Limited will be held on Tuesday, 30th day of November, 2021 at 05.00 PM at the registered office of the Company situated at F-46, Pankaj Central Market I.P Extension, Patparganj New Delhi - 110092 to transact the following business:

Ordinary business:

1. To consider, approve and adopt the Audited Financial Statements of the Company comprising the Balance Sheet as on March 31, 2021, Statement of Profit & Loss for the year ended on that date and Notes thereto together with the Report of the Board of Directors and Auditors' thereon.
2. To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 139 (1), Section 141, Section 142 and other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), approval of the Members be and is hereby accorded for the re-appointment of **M/s. Rishi Kapoor & Company**, Chartered Accountants (Firm Registration Number 006615C) as the Statutory Auditors of the Company for a period of 5 years to hold office from the conclusion of this Annual General Meeting till the conclusion of 29th Annual General Meeting of the Company to be held in the year 2026 at such remuneration as may be mutually agreed by the Company with the Statutory Auditors of the Company."

Date: 02nd September 2021

Place: Delhi

By the Order of the Board of
Rodec Pharmaceuticals Private Limited


Mukesh Kumar Gupta
(Director)
DIN-00555175

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

Notes:

- (1) A MEMBER ENTITLED TO ATTEND AND VOTE AT MEETING IS ENTITLED TO APPOINT THE PROXY TO ATTEND AND VOTE AT THE MEETING IN CASE OF POLL ON HIS BEHALF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY.
- (2) The instrument of proxy, duly stamped and signed shall be deposited at the registered office not less than 48 hours before the commencement of the meeting.
- (3) The relevant explanatory statement pursuant to Section 102 of the Companies Act, 2013 relating to the Special Business to be transacted at the meeting is annexed hereto.
- (4) All documents referred to in the notice and accompanying explanatory statement are open for inspection at the registered office of the Company on all working days during business hours up to the date of the general meeting and at the venue of the meeting for the duration of the meeting.

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

BOARD REPORT

Dear Members,

Your Directors have pleasure in presenting **24th** annual report on the affairs of the Company together with the Audited Statement of Accounts for the year ended on 31st March, 2021.

FINANCIAL SUMMARY OR PERFORMANCE OF THE COMPANY:

| Particulars | (In Rupees) | |
|--|--------------------------|--------------------------|
| | Year ended 31.03.2021 | Year ended 31.03.2020 |
| Gross Revenue | 462733859.39 | 334458890.56 |
| Less: Total Expenditure | 416556160.25 | 309141487.04 |
| Profit/ (Loss) before Tax | 46177699.14 | 25317403.52 |
| Less: | | |
| -Current Tax | 12000000.00 | 6775000.00 |
| -Current Tax Expenses Relating For Prior Years | 149561.00 | 94994.00 |
| -Deferred Tax | -116891.00 | 123196.00 |
| Profit / (Loss) for the period | 34145029.14 | 18324213.52 |

OPERATIONS PERFORMANCE:

The Company has reported total gross revenue of ₹**462733859.39** for the current year as compared to ₹**334458890.56** in the previous year. The Net Profit for the year under review is amounted to ₹**34145029.14** as compared to ₹**18324213.52** in the previous year.

TRANSFER TO RESERVES

During the year under review, the Company has not transferred any fund to general reserves.

DIVIDEND

Considering the future needs of the Company for expansion and growth and to strengthen the financial position of the Company, your directors do not recommend any dividend for the financial year ended March 31, 2021.

DEPOSITS:

The Company has not invited or accepted any deposits from the public during the year ended March 31, 2021. There were no unclaimed or unpaid deposits as on March 31, 2021.

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR.

There have been no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

DETAILS OF SUBSIDIARY/JOINT VENTURES/ASSOCIATE COMPANIES:

There is no subsidiary company or joint venture or associate company .

CHANGE IN THE NATURE OF BUSINESS :

There is no change in the nature of the business of the company.

CHANGES IN SHARE CAPITAL:

There was no change in the Share Capital of the company during the year.

- **DISCLOSURE REGARDING ISSUES OF EQUITY SHARES WITH DIFFERENTIAL RIGHTS:** The Company has not issues any equity shares with differential rights during the year under review.
- **DISCLOSURE REGARDING ISSUES OF EMPLOYEE STOCK OPTIONS:** The Company has not provided any Stock Option Scheme to the employees during the year under review.
- **DISCLOSURE REGARDING THE ISSUES OF SWEAT EQUITY SHARES:** The Company has not issued any Sweat Equity Shares during the year under review.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3) (m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, is annexed herewith as **Annexure A**.

DETAILS OF DIRECTORS OR KEY MANAGERIAL PERSONNEL:

There is no change in the Directorship of the Company during the financial year 2020-2021.

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

DECLARATION BY INDEPENDENT DIRECTORS

The Company is not required to appoint Independent Directors under Section 149(4) and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 hence no declaration has been obtained.

EXTRACT OF THE ANNUAL RETURN IN FORM MGT-9:

Pursuant to section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014, Form MGT-9 is given in **Annexure-B**.

STATUTORY AUDITOR & AUDIT REPORT:

M/s **Rishi Kapoor & Company, Chartered Accountants (Firm Reg. No. 006615C)**, the existing auditors firm of the Company, was re-constituted from proprietorship firm to partnership firm with effect from 30.06.2021 and they intimated the members of the Company at their Company vide letter dated 01.07.2021. The Members of the Company have appointed them as Statutory Auditors of the Company for the financial year 2020-21 until the conclusion of this ensuing Annual General Meeting. Accordingly, the tenure of the partnership firm M/s Rishi Kapoor & Company, Chartered Accountants (Firm Reg. No. 006615C) will expire at this ensuing Annual General Meeting.

Subject to the approval of the members of the Company, the Board recommended the re-appointment M/s Rishi Kapoor & Company, Chartered Accountants (Firm Reg. No. 006615C) as Statutory Auditors of the Company for a period of five years to hold office from the conclusion of this Annual General Meeting till the conclusion of 29th Annual General Meeting of the Company to be held in the year 2026. They have submitted their written consent that they are eligible to hold office as Statutory Auditors of the Company in terms of Section 139 of the Act and that they also satisfy the criteria provided in Section 141 of the Companies Act.

The Auditors' Report with notes to accounts are self-explanatory and, therefore, do not call for further comments. The Audit Report does not contain any qualification, reservation or adverse remarks.

REPORTING OF FRAUDS BY AUDITORS:

During the year under review, the statutory auditors has not reported to the Board, under sub-section (12) of section 143 of the Companies Act, 2013 any instances of fraud committed against the Company by its officers or employees, the details of which would need to be mentioned in the Board's report.

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

NUMBER OF MEETING OF THE BOARD:

During the year, the Board Meetings were convened are as follow and the intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

| Sr No. | Date of Board Meeting | Number of Director Required to attend | Number of Director attended the meeting |
|---------------|------------------------------|--|--|
| 1 | 01/04/2020 | 3 | 3 |
| 2 | 25/06/2020 | 3 | 3 |
| 3 | 15/09/2020 | 3 | 3 |
| 4 | 19/11/2020 | 3 | 3 |
| 5 | 09/12/2020 | 3 | 3 |
| 6 | 03/03/2021 | 3 | 3 |

CORPORATE SOCIAL RESPONSIBILITY:

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility. However, your company respects society value and makes endeavor to contribute for the societal clause as far as possible.

AUDIT COMMITTEE

The provisions of Section 177 of the Companies Act, 2013 read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2013 relating to composition of Audit Committee is not applicable to the Company.

COMMITTEES OF THE BOARD:

The Provisions of section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of the Board and its Powers) Rules 2014, is not applicable on the company, hence our company is not required to constitute Nomination and Remuneration committee.

The Company is also not required to constitute stakeholders Relationship committee under section 178(5) of the companies Act, 2013.

DISCLOSURE ON ESTABLISHMENT OF A VIGIL MECHANISM

The provisions of Section 177 (9) of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of the Board and its Powers) Rules, 2014 with respect to establishment of Vigil Mechanism is not applicable to the Company.

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

The Company has Internal Complaint Committee in compliance with the provisions of the Sexual Harassment of Women at workplace (Prevention, Prohibition & Redressal) Act, 2013. The details are as follows:

1. Number of Complaints of sexual harassment received in the year: Nil
2. Number of complaints disposed during the year: N.A
3. No. of cases pending for more than ninety days: N.A
4. No. of workshops or awareness programme against sexual harassment carried out: None
5. Nature of action taken by the employer or District officer: N.A

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

During the year under review, there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

DIRECTORS' RESPONSIBILITY STATEMENT U/S SECTION 134:

Pursuant to the requirement under section 134(3)(c) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

(i) In the preparation of the annual accounts for the financial year ended 31st March, 2021, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(ii) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2021 and of the profit and loss of the company for that period;

(iii) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(iv) The directors had prepared the annual accounts on a going concern basis; and

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

(v) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

SECRETARIAL AUDIT UNDER SECTION 204 OF THE COMPANIES ACT, 2013

Pursuant to the provisions of section 204 of the companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 Secretarial Audit does not apply to the company.

MAINTENANCE OF COST RECORDS:

In accordance with the provisions under Section 148 of the Companies Act, 2013 read with the rules made there under, the provisions relating to the cost Audit are not applicable on the Company.

BUSINESS RISK MANAGEMENT:

Pursuant to section 134(3) (n) of the Companies Act, 2013, the Company has developed and implemented a risk management policy which identifies major risks that may affect the Company. The same has also been adopted by the Board and is also subject to its review from time to time. Further, risk mitigation process and its related measures have been also formulated as well as spelled out in the said policy.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:

The particulars of loans, guarantees or investments made during the Financial Year 2020-21, if any, have been disclosed in the notes attached to and forming part of the Financial Statements of the Company prepared for the Financial Year ended March 31, 2021, as per the provisions of Section 186 and Section 134(3)(g) of the Companies Act, 2013.

RELATED PARTY TRANSACTIONS:

Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 in the form AOC-2 is attached as **Annexure-C**. All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business.

STATEMENT IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROL WITH REFERENCE TO THE FINANCIAL STATEMENTS

The management has taken all necessary steps to plug the internal control weaknesses. The management has implemented an effective and meaningful system in place to safeguard the assets of the company.

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

PARTICULARS OF EMPLOYEES:

None of the employees who have worked throughout the year or a part of the Financial Year 2020-21, were getting remuneration in excess of the threshold mentioned under Section 197(12) of the Act read with rule 5(2) of Companies (Appointment and Remuneration) Rules, 2014.

THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR:

During the Financial Year 2020-21, there was no application made and proceeding initiated /pending under the Insolvency and Bankruptcy Code, 2016, by any Financial and/or Operational Creditors against your Company. As on the date of this report, there is no application or proceeding pending against your company under the Insolvency and Bankruptcy Code, 2016

SECRETARIAL STANDARDS:

Your Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS-1) and Secretarial Standards on General Meetings (SS-2) issued by the Institute of Company Secretaries of India ("ICSI") as may be amended from time to time.

ACKNOWLEDGMENTS:

Directors of the company take this opportunity to place on record their appreciation and sincere gratitude to the Government and the Bankers to the Company for their valuable support and look forward to their continued co-operation in the years to come.

Directors acknowledge the support and co-operation received from the employees and all those who have helped in the day to day management.

Date: 02nd September 2021

Place: Delhi

For and on behalf of the Board of Directors of
Rodec Pharmaceuticals Private Limited


Mukesh Kumar Gupta
(Director)
DIN-00555175


Chhaya Gupta
(Director)
DIN-00560474

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

Annexure - A

Information under Section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) the Companies (Accounts) Rules, 2014 and forming part of the Report of the Directors

(A) Conservation of energy-

(i) the steps taken or impact on conservation of energy: NIL

(ii) the steps taken by the company for utilising alternate sources of energy: NIL

(iii) the capital investment on energy conservation equipments: NIL

(B) Technology absorption-

(i) the efforts made towards technology absorption: NIL

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution: NIL

(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)- : NIL

(iv) the expenditure incurred on Research and Development: NIL

(C) Foreign exchange earnings and Outgo-

During the year, there was no foreign exchange inflow or outflow under the review.

Date: 02nd September 2021

Place: Delhi

For and on behalf of the Board of Directors of
Rodec Pharmaceuticals Private Limited


Mukesh Kumar Gupta
(Director)
DIN-00555175


Chhaya Gupta
(Director)
DIN-00560474

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

Annexure-B

Form No. MGT- 9

Extract of Annual Return

As on financial year ended on 31.03.2021

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company
(Management & Administration) Rules, 2014

I. REGISTRATION & OTHER DETAILS:

| | | |
|----|--|---|
| 1. | CIN | U24233DL1997PTC090729 |
| 2. | Registration Date | 18.11.1997 |
| 3. | Name of the Company | RODEC PHARMACEUTICALS PRIVATE LIMITED |
| 4. | Category/Sub-category of the Company | Company Limited by Shares/Indian Non-Government Company |
| 5. | Address of the Registered office & contact details | F-46, Pankaj Central Market, I.P. Extension, Patparganj New Delhi, Delhi- 110092 |
| 6. | Whether listed company | Unlisted |
| 7. | Name, Address & contact details of the Registrar & Transfer Agent, if any. | NA |

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

| S. No. | Name and Description of main products / services | NIC Code of the Product/service | % to total turnover of the company |
|--------|--|---------------------------------|------------------------------------|
| 1 | Trading & Marketing of Pharmaceuticals | Division 64 | 100 |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

| | | | | | | | | | |
|--|-----|----------|----------|--------|-----|----------|----------|--------|-----------|
| i) Others (specify) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sub-total (B)(1):- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2. Non-Institutions | | | | | | | | | |
| a) Bodies Corp. | | | | | | | | | |
| | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NO CHANGE |
| i) Indian | | | | | | | | | |
| ii) Overseas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| b) Individuals | | | | | | | | | |
| i) Individual shareholders holding nominal share capital upto Rs. 1 lakh | 0 | 600.00 | 600.00 | 0.58% | 0 | 600.00 | 600.00 | 0.58% | NO CHANGE |
| ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh | 0 | 13500.00 | 13500.00 | 13.03% | NIL | 13500.00 | 13500.00 | 13.03% | NO CHANGE |
| c) Others (HUF) | 0 | 300.00 | 300.00 | 0.29% | 0 | 300.00 | 300.00 | 0.29% | NO CHANGE |
| Sub-total (B)(2):- | NIL | 14400.00 | 14400.00 | 13.90% | NIL | 14400.00 | 14400.00 | 13.90% | NO CHANGE |
| Total Public Shareholding (B)=(B)(1)+(B)(2) | NIL | 14400.00 | 14400.00 | 13.90% | NIL | 14400.00 | 14400.00 | 13.90% | NO CHANGE |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

| | | | | | | | | | |
|---|------------|------------------|------------------|-------------|------------|------------------|------------------|-------------|------------------|
| C. Shares held by Custodian for GDRs & ADRs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grand Total (A+B+C) | NIL | 103600.00 | 103600.00 | 100% | NIL | 103600.00 | 103600.00 | 100% | NO CHANGE |

ii) Shareholding of Promoter-

| S.L.No. | Shareholder's Name | Shareholding at the beginning of the year | | | Shareholding at the end of the year | | | % change in shareholding during the year |
|---------|--------------------|---|----------------------------------|--|-------------------------------------|----------------------------------|--|--|
| | | No. of Shares | % of total Shares of the company | % of Shares Pledged / encumbered to total shares | No. of Shares | % of total Shares of the company | % of Shares Pledged / encumbered to total shares | |
| 1. | Mukesh Kumar Gupta | 61100 | 58.98% | - | 61100 | 58.98% | - | NO CHANGE |
| 2. | Chhaya Gupta | 28100 | 27.12% | - | 28100 | 27.12% | - | NO CHANGE |
| | Total | 89200 | 86.10% | - | 89200 | 86.10% | - | NO CHANGE |

iii) Change in Promoters' Shareholding (please specify, if there is no change)

| SL. No. | | Shareholding at the beginning of the year | | Cumulative Shareholding during the year | |
|---------|----------------------------------|---|----------------------------------|---|----------------------------------|
| | | No. of shares | % of total shares of the company | No. of shares | % of total shares of the company |
| 1. | Mukesh Kumar Gupta | | | | |
| | At the beginning of the year | 61100 | 58.98% | 61100 | 58.98% |
| | Date wise Increase / Decrease in | NIL | NIL | NIL | NIL |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

| | | | | | |
|----|---|--------------|---------------|--------------|---------------|
| | Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc.): | | | | |
| | At the end of the year | 61100 | 58.98% | 61100 | 58.98% |
| 2. | Chhaya Gupta | | | | |
| | At the beginning of the year | 28100 | 27.12% | 28100 | 27.12% |
| | Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc.): | NIL | NIL | NIL | NIL |
| | At the end of the year | 28100 | 27.12% | 28100 | 27.12% |

iv) Shareholding Pattern of top ten Shareholders(Other than Directors, Promoters and Holders of GDRs and ADRs):

| SL. No | | Shareholding at the beginning of the year | | Cumulative Shareholding during the year | |
|--------|--|---|----------------------------------|---|----------------------------------|
| | | No. of shares | % of total shares of the company | No. of shares | % of total shares of the company |
| 1. | Mukesh Kumar Gupta (HUF) | | | | |
| | At the beginning of the year | 300 | 0.29% | 300 | 0.29% |
| | Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc): | NIL | NIL | NIL | NIL |
| | At the end of the year (or on the date of separation, if separated during the year) | 300 | 0.29% | 300 | 0.29% |
| 2. | Others | | | | |
| | At the beginning of the year | 14100 | 13.61% | 14100 | 13.61% |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

| | | | | |
|--|-------|--------|-------|--------|
| Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc): | NIL | NIL | - | - |
| At the end of the year (or on the date of separation, if separated during the year) | 14100 | 13.61% | 14100 | 13.61% |

v) Shareholding of Directors and Key Managerial Personnel:

| SL. No. | | Shareholding at the beginning of the year | | Cumulative Shareholding during the year | |
|---------|---|---|----------------------------------|---|----------------------------------|
| | | No. of shares | % of total shares of the company | No. of shares | % of total shares of the company |
| 1. | Mr. Mukesh Kumar Gupta | | | | |
| | At the beginning of the year | 61100 | 58.98% | 61100 | 58.98% |
| | Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.): | NIL | NIL | - | - |
| | At the end of the year | 61100 | 58.98% | 61100 | 58.98% |
| 2. | Smt. Chhaya Gupta | | | | |
| | At the beginning of the year | 28100 | 27.12% | 28100 | 27.12% |
| | Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc.): | NIL | NIL | NIL | NIL |
| | At the end of the year | 28100 | 27.12% | 28100 | 27.12% |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

V. INDEBTEDNESS -

Indebtedness of the Company including interest outstanding/accrued but not due for payment

| | Secured Loans excluding deposits | Unsecured Loans | Deposits | Total Indebtedness |
|--|--|---------------------|------------|-----------------------|
| Indebtedness at the beginning of the financial year | | | | |
| (i) Principal Amount | 41870565.99 | 2814089.00 | NIL | 44684654.99 |
| (ii) Interest due but not paid | NIL | NIL | NIL | NIL |
| (iii) Interest accrued but not due | NIL | NIL | NIL | NIL |
| Total (i+ii+iii) | 41870565.99 | 2814089.00 | NIL | 44684654.99 |
| Change in Indebtedness during the financial year | | | | |
| * Addition | NIL | 29,53,331.00 | NIL | 29,53,331.00 |
| * Reduction | 9867665.48 | NIL | NIL | (9867665.48) |
| Net Change | (9867665.48) | 29,53,331.00 | NIL | (6914334.48) |
| Indebtedness at the end of the financial year | | | | |
| (i) Principal Amount | 32002900.51 | 5767420.00 | NIL | 37770320.51 |
| (ii) Interest due but not paid | NIL | NIL | NIL | NIL |
| (iii) Interest accrued but not due | NIL | NIL | NIL | NIL |
| Total (i+ii+iii) | 32002900.51 | 5767420.00 | NIL | 51329159.58 |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

| SL. No. | Particulars of Remuneration | Name of MD/WTD/ Manager | | | Total Amount |
|---------|---|-------------------------|-------------------|-------------------|-------------------|
| | | Mukesh Kumar Gupta | Shubhangi Gupta | Chaya Gupta | |
| | | | | | --- |
| 1 | Gross salary | 6000000.00 | 1800000.00 | 1800000.00 | 7950000.00 |
| | (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 | ----- | ---- | ---- | --- |
| | (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 | ----- | ---- | ---- | --- |
| | (c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961 | ----- | ---- | ---- | --- |
| 2 | Stock Option | ----- | ---- | ---- | --- |
| 3 | Sweat Equity | ----- | ---- | ---- | --- |
| 4 | Commission - as % of profit - others, specify... | ----- | ---- | ---- | --- |
| 5 | Others, please specify | ----- | ---- | ---- | --- |
| | Total (A) | 6000000.00 | 1800000.00 | 1800000.00 | 7950000.00 |
| | Ceiling as per the Act | ----- | ---- | ---- | --- |

B. Remuneration to other directors

| SN. | Particulars of Remuneration | Name of Directors | | | Total Amount |
|-----|--|-------------------|---|---|--------------|
| | | | | | |
| 1 | Independent Directors | - | - | - | - |
| | Fee for attending board committee meetings | - | - | - | - |
| | Commission | - | - | - | - |
| | Others, please specify | - | - | - | - |
| | Total (1) | - | - | - | - |
| 2 | Other Non-Executive Directors | - | - | - | - |
| | Fee for attending board committee meetings | - | - | - | - |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

| | | | | |
|--------------------------------|---|---|---|---|
| Commission | - | - | - | - |
| Others, please specify | - | - | - | - |
| Total (2) | - | - | - | - |
| Total (B)=(1+2) | - | - | - | - |
| Total Managerial Remuneration | - | - | - | - |
| Overall Ceiling as per the Act | - | - | - | - |

C. Remuneration to key managerial personnel other than md/manager/wtd

| SN | Particulars of Remuneration | Key Managerial Personnel | | | |
|----|---|--------------------------|-------------------|------|-------|
| | | CEO | Company Secretary | CFO | Total |
| 1 | Gross salary | ---- | ---- | ---- | --- |
| | (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 | ---- | ---- | ---- | --- |
| | (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 | ---- | ---- | ---- | --- |
| | (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 | ---- | ---- | ---- | --- |
| 2 | Stock Option | ---- | ---- | ---- | --- |
| 3 | Sweat Equity | ---- | ---- | ---- | --- |
| 4 | Commission | ---- | ---- | ---- | --- |
| | - as % of profit | ---- | ---- | ---- | --- |
| | - others, specify... | ---- | ---- | ---- | --- |
| 5 | Others, please specify | ---- | ---- | ---- | --- |
| | Total | ---- | ---- | ---- | --- |

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

| Type | Section of the Companies Act | Brief Description | Details of Penalty / Punishment/ Compounding fees imposed | Authority [RD / NCLT/ COURT] | Appeal made, if any (give Details) |
|-------------------------------------|------------------------------|-------------------|---|------------------------------|------------------------------------|
| A. COMPANY | | | | | |
| Penalty | NIL | NIL | NIL | NIL | NIL |
| Punishment | NIL | NIL | NIL | NIL | NIL |
| Compounding | NIL | NIL | NIL | NIL | NIL |
| B. DIRECTORS | | | | | |
| Penalty | NIL | NIL | NIL | NIL | NIL |
| Punishment | NIL | NIL | NIL | NIL | NIL |
| Compounding | NIL | NIL | NIL | NIL | NIL |
| C. OTHER OFFICERS IN DEFAULT | | | | | |
| Penalty | NIL | NIL | NIL | NIL | NIL |
| Punishment | NIL | NIL | NIL | NIL | NIL |
| Compounding | NIL | NIL | NIL | NIL | NIL |

Date: 02nd September 2021
Place: Delhi

For and on behalf of the Board of Directors of
Rodec Pharmaceuticals Private Limited


Mukesh Kumar Gupta
(Director)
DIN-00555175


Chhaya Gupta
(Director)
DIN-00560474

RODEC PHARMACEUTICALS PRIVATE LIMITED

F-46, Pankaj Central Market, I.P. Extension, Patparganj, New Delhi, Delhi- 110092,

CIN- U24233DL1997PTC090729, Email ID- shiplasharma@rodec.in

Contact No. 0120-4176800

Annexure-C

Form AOC-2

Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014:

1. Details of contracts or arrangements or transactions not at arm's length basis: Nil

2. Details of material contracts or arrangement or transactions at arm's length basis:


| Name (s) of the related party and nature of relationship | Nature of the contracts/ arrangement/ transactions. | Duration of the contracts/ arrangements / transactions. | Salient terms of the contracts or arrangements or transactions including the value, if any: | Date(s) of approval by the Board, if any: | Amount paid as advances, if any: |
|--|---|---|---|---|----------------------------------|
| Rodec Healthcare (P) Ltd, Director Interested | Purchase | 1 Year | Purchase of Rs. 3142349.74/- | 01/04/2020 | - |
| Nupur Gupta, Relative of Director | Payment of Salary | 1 Year | Payment of Salary of Rs. 9,00,000/- | 01/04/2020 | |

Date: 02nd September 2021

Place: Delhi

For and on behalf of the Board of Directors of
Rodec Pharmaceuticals Private Limited


Mukesh Kumar Gupta
(Director)
DIN-00555175


Chhaya Gupta
(Director)
DIN-00560474



**RISHI KAPOOR & COMPANY
CHARTERED ACCOUNTANTS**

Plot No. 10, Advocate Chambers, RDC, Raj Nagar
GHAZIABAD 201002

Phones: 0120-4371050, Fax: 4371070, (M) 9910385499 Email: carishikapoor@yahoo.co.in
CIN: U24233DL1997PTC090729

INDEPENDENT AUDITOR'S REPORT

**TO
THE MEMBERS OF
RODEC PHARMACEUTICALS PRIVATE LIMITED**

REPORT ON THE FINANCIAL STATEMENTS

We have audited the accompanying financial statements of **RODEC PHARMACEUTICALS PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss (including other comprehensive incomes) and the statement of Cash Flows and the statement of changes in equity for the year then ended and a summary of the significant accounting policies and other explanatory information.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The management and Board of Directors of the Company are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the act') with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive incomes and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act, read with rule 7 of Companies (Accounts) Rules, 2014.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.



We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Director, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

OPINION

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards, the financial position of the Company as at 31st March 2021 and its financial performance and its cash flows for the year ended on that date.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure – A and Note No.23, a statement on the matters Specified in paragraphs 3 and 4 of the Order.
2. As required by section 143(3) of the Act, we further report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) The Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;



Annexure A to the Independent Auditors' Report

The Annexure referred to in Independent Auditors Report to the Members of the Company on the Financial Statements for the year ended 31st March 2021, we report that:

- i. According to the information and explanations given to us and on the basis of our examination of the records of the Company in respect of its fixed assets :
 - (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
 - (b) The fixed assets have been physically verified by the management at regular intervals; certain fixed assets were verified during the year and no material discrepancies were noticed on such verification, and in our opinion, this periodicity of physical verification is reasonable having regard to the size of the company and the nature of its assets;
 - (c) The title deeds of immovable properties are held in the name of the company.
- ii. In our opinion on the basis of information and explanation given to us in respect of its inventories :
 - (a) The inventory has been physically verified during the year by the management and the frequency of verification is reasonable;
 - (b) The procedures of physical verification of inventories followed by the Management were reasonable and adequate in relation to the size of the company and nature of its business;
 - (c) The Company has maintained proper records of its inventories and no material discrepancies were noticed on physical verification.
- iii. The company has not granted loans, secured or unsecured to/from companies, LLP, firms or other parties covered in the register maintained under section 189 of the Act.
 - (a) In our opinion, the rate of interest and other terms and conditions on which the loans had been granted to the bodies corporate listed in the register maintained under Section 189 of the Act were not, prima facie, prejudicial to the interest of the Company;
 - (b) In the case of the loans granted to the bodies corporate listed in the register maintained under section 189 of the Act, the borrowers have been regular in the payment of the principal and interest as stipulated;
 - (c) There are no overdue amounts in respect of the loan granted to a body corporate listed in the register maintained under section 189 of the Act.
- iv. In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the companies Act, 2013 in respect of loans, investments, guarantees and security.



- v. The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and provisions of Sections 73 to 76 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2015 with regard to the deposits accepted are not applicable.
- vi. In our opinion the Central Government has not prescribed maintenance of cost records under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- vii. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, income-tax, sales tax, value added tax, duty of customs, service tax, cess and other material statutory dues have been generally/regularly deposited during the year by the Company with the appropriate authorities.
- (b) There are no dues of Income Tax, Wealth Tax, Service Tax, Sales Tax, Customs Duty and Excise Duty which have not been deposited on account of any disputes.
- viii. In our opinion and according to the information and explanation given to us, the company has not defaulted in the repayment of dues to financial institution or banks and debenture-holders.
- ix. Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised moneys by way of initial public offer or further public offer including debt instruments and term loans. Accordingly, the provisions of clause 3(ix) of the Order are not applicable to the company and hence not commented upon.
- x. During the course of our examination of the books and records of the company, carried in accordance with the auditing standards generally accepted in India, we have neither come across any instance of fraud on or by the Company noticed or reported during the course of our audit nor have we been informed of any such instance by the Management.
- xi. Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration with the requisite approvals mandated by the provisions of section 197 read with Schedule V of the Companies Act are not applicable to the company.
- xii. In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4(xii) of the Order are not applicable to the Company.
- xiii. In our opinion, all transactions with related parties are in compliance with section 177 and 188 of the Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.



- d) In our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014;
- e) On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164(2) of the Act;
- f) In our opinion, the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls are adequate in commensurate to the size of the business.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanation given to us;
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the company.

Place: Ghaziabad
Date : 02.09.2021

For Rishi Kapoor & Company
Chartered Accountants
FRNo. 006615C



(Rishi Kapoor)
Partner
M.No.075483

- xiv. Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3(xiv) of the Order are not applicable to the company and hence not commented upon.
- xv. Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3(xv) of the Order are not applicable to the company and hence not commented upon.
- xvi. In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3(xvi) of the Order are not applicable to the Company and hence not commented upon.

Place : Ghaziabad
Date : 02.09.2021

For Rishi Kapoor & Company
Chartered Accountants
FRNo. 006615C




(Rishi Kapoor)
Partner
M.No.075483

RODEC PHARMACEUTICALS PRIVATE LIMITED
CIN : U24233DL1997PTC090729
BALANCE SHEET AS AT 31st MARCH,2021

| PARTICULARS | NOTE NO. | AS AT 31.03.2021 | AS AT 31.03.2020 |
|--|----------|----------------------------|----------------------------|
| I. EQUITY & LIABILITIES | | | |
| 1. SHAREHOLDER' FUNDS | | | |
| a Share Capital | 1 | 1036000.00 | 1036000.00 |
| b Reserves & Surplus | 2 | 116664372.91 | 82519343.77 |
| c Money received against Share Warrants | | - | - |
| 2. SHARE APPLICATION MONEY PENDING ALLOTMENT | | | |
| 3. NON CURRENT LIABILITIES | | | |
| a Long Term Borrowings | 3 | 18284493.71 | 4004696.36 |
| b Deferred Tax Liabilities (Net) | - | - | - |
| c Other Long Term Liabilities | 4 | 3700000.00 | 4100000.00 |
| d Long Term Provisions | 5 | - | - |
| 4. CURRENT LIABILITIES | | | |
| a Short Term Borrowings | 6 | 19485826.80 | 40679958.63 |
| b Trade Payables | 7 | 32873546.93 | 24936187.48 |
| c Other Current Liabilities | 8 | 27168416.04 | 17421793.45 |
| d Short Term Provisions | 9 | 12000000.00 | 6775000.00 |
| TOTAL Rs. | | <u><u>231212656.39</u></u> | <u><u>181472979.69</u></u> |
| II. ASSETS | | | |
| 1. NON CURRENT ASSETS | | | |
| a Fixed Assets | | | |
| (i) Tangible Assets | 10 | 76109584.34 | 6950352.96 |
| (ii) Intangible Assets | - | - | - |
| (iii) Capital Work In Progress | - | - | - |
| (iv) Intangible Assets Under Development | - | - | - |
| (v) Fixed Assets held for Sale | - | - | - |
| b Non Current Investments | - | - | - |
| c Deferred Tax Assets (Net) | 11 | 827953.00 | 711062.00 |
| d Long Term Loans & Advances | 12 | 10521012.61 | 557826.78 |
| e Other Non Current Assets | - | - | - |
| 2. CURRENT ASSETS | | | |
| a Current Investments | - | - | - |
| b Inventories | 13 | 14590862.00 | 11864522.00 |
| c Trade Receivables | 14 | 75675391.67 | 72864950.96 |
| d Cash & Cash Equivalents | 15 | 472104.38 | 1680573.34 |
| e Short Term Loans & advances | 16 | 53015748.39 | 86843691.65 |
| f Other Current Assets | - | - | - |
| TOTAL Rs. | | <u><u>231212656.39</u></u> | <u><u>181472979.69</u></u> |
| Significant Accounting Policies and Notes on Account | 24 | - | - |

As per our report of even date
For Rishi Kapoor & Company
Chartered Accountants

FRNo.006615C



(Rishi Kapoor)
Partner
M.No.075483

For and on behalf of the Board of Directors


(MUKESH KUMAR GUPTA)
Director
Din No : 00555175


(CHHAYA GUPTA)
Director
Din No : 00560474

Place : Ghaziabad

Date : 02.09.2021

UDIN : 21075483AAAAQZ7587

RODEC PHARMACEUTICALS PRIVATE LIMITED
CIN : U24233DL1997PTC090729
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2021

| PARTICULARS | NOTE NO. | FOR THE YEAR ENDED 31.03.2021 | FOR THE YEAR ENDED 31.03.2020 |
|---|-----------|-------------------------------------|-------------------------------------|
| I. CONTINUING OPERATIONS | | | |
| 1 REVENUE FROM OPERATIONS (NET) | 17 | 457451411.28 | 327345935.58 |
| | TOTAL Rs. | <u>457451411.28</u> | <u>327345935.58</u> |
| 2 EXPENSES | | | |
| a Cost of Material Consumed | - | - | - |
| b Purchase of Stock In Trade | 18 | 191474233.31 | 138989933.85 |
| c Change in Inventories of Finished Goods, Work In Progress & Stock In Trade | 19 | -2726340.00 | -4180012.24 |
| d Employee Benefit Expenses | 20 | 118247581.46 | 98430738.61 |
| e Other Expenses | 21 | 103528055.98 | 68593860.70 |
| | TOTAL Rs. | <u>410523530.75</u> | <u>301834520.92</u> |
| 3 Earning Before Exceptional Items, Extraordinary Items, Interest, Tax, Depreciation & Amortisation (EBDITA) (1-2) | | 46927880.53 | 25511414.66 |
| 4 Finance Costs | 22 | 3787689.43 | 5473103.86 |
| 5 Depreciation & Amortisation Expenses | 10 | 2244940.07 | 1833862.26 |
| 6 Other Income | 23 | 5282448.11 | 7112954.98 |
| 7 Profit / (Loss) before Exceptional & Extraordinary Items & Tax (3+/-4+/-5+/-6) | TOTAL Rs. | <u>46177699.14</u> | <u>25317403.52</u> |
| 8 Exceptional Items | | - | - |
| 9 Profit / (Loss) before Extraordinary Items & Tax (7+/-8) | TOTAL Rs. | <u>46177699.14</u> | <u>25317403.52</u> |
| 10 Extraordinary Items | | - | - |
| 11 Profit / (Loss) before Tax (9+/-10) | TOTAL Rs. | <u>46177699.14</u> | <u>25317403.52</u> |
| 12 Tax Expenses | | | |
| a Current Tax Expenses for Current Year | | 12000000.00 | 6775000.00 |
| b MAT Credit (Where applicable) | | - | - |
| c Current Tax Expenses Relating to Prior Years | | 149561.00 | 94994.00 |
| d Net Current Tax Expenses | | 12149561.00 | 6869994.00 |
| e Deferred Tax Liability (Asset) | | -116891.00 | 123196.00 |
| | TOTAL Rs. | <u>12032670.00</u> | <u>6993190.00</u> |
| 13 Profit / (Loss) from Continuing Operations (11+/- 12) | | 34145029.14 | 18324213.52 |
| 2 DISCONTINUING OPERATIONS | | | |
| 14.i Profit / (Loss) from Discontinuing Operations Before Tax | | - | - |
| 14.ii Gain / (Loss) on Disposal of Assets / Settlement of Liabilities Discontinuing Operations | | - | - |
| 14.iii Add / (Less) : Tax Expenses of Discontinuing Operations | | - | - |
| a on Ordinary Activities Attributable to the Discontinuing Operations | | - | - |
| b on Gain / (Loss) on Disposal of Assets / Settlement of Liabilities | | - | - |
| 15 Profit / (Loss) from Discontinuing Operations (14.i+/- 14.ii+/- 14.iii) | | - | - |
| 3 TOTAL OPERATIONS | | | |
| 16 Profit / (Loss) For the Year (13+/-15) | TOTAL Rs. | 34145029.14 | 18324213.52 |



RODEC PHARMACEUTICALS PRIVATE LIMITED
CIN : U24233DL1997PTC090729
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2021

| PARTICULARS | NOTE NO. | FOR THE YEAR ENDED 31.03.2021 | FOR THE YEAR ENDED 31.03.2020 |
|---|-----------|-------------------------------------|-------------------------------------|
| 17.i Earning per Share (of Rs.10/- each) : | | | |
| a Basic | | | |
| (i) Continuing Operations | | 329.59 | 176.87 |
| (ii) Total Operations | | 329.59 | 176.87 |
| b Diluted | | | |
| (i) Continuing Operations | | 329.59 | 176.87 |
| (ii) Total Operations | | 329.59 | 176.87 |
| 17.ii Earning per Share (excluding extraordinary items) (of Rs. 10/- each) : | | | |
| a Basic | | | |
| (i) Continuing Operations | | 329.59 | 176.87 |
| (ii) Total Operations | | 329.59 | 176.87 |
| b Diluted | | | |
| (i) Continuing Operations | | 329.59 | 176.87 |
| (ii) Total Operations | | 329.59 | 176.87 |
| Significant Accounting Policies and Notes on Account | 24 | | |

As per our report of even date
For Rishi Kapoor & Company
Chartered Accountants
FRNo.006615C

(Rishi Kapoor)
Partner
M.No.075483



For and on behalf of the Board of Directors


(MUKESH KUMAR GUPTA)
Director
Din No : 00555175


(CHHAYA GUPTA)
Director
Din No : 00560474

Place : Ghaziabad

Date : 02.09.2021

UDIN : 21075483AAAAQZ7587

NOTES ON ACCOUNT

| Note No. - | AS AT 31.03.2021 | | AS AT 31.03.2020 | |
|--|------------------|-------------------|------------------|-------------------|
| | Number | Amount | Number | Amount |
| A SHARE CAPITAL | | | | |
| a AUTHORISED CAPITAL | | | | |
| Equity shares of Rs. 10/- each with voting rights | 250000 | 2500000.00 | 250000 | 2500000.00 |
| Equity shares of Rs. 10/- each with differential voting rights | - | - | - | - |
| Compulsorily convertible preference shares of Rs. 10/- each | - | - | - | - |
| Optionally convertible preference shares of Rs. 10/- each | - | - | - | - |
| Redeemable preference shares of Rs. 10/- each | - | - | - | - |
| TOTAL | 250000 | 2500000.00 | 250000 | 2500000.00 |
| b ISSUED CAPITAL | | | | |
| Equity shares of Rs. 10/- each with voting rights | 103600 | 1036000.00 | 103600 | 1036000.00 |
| Equity shares of Rs. 10/- each with differential voting rights | - | - | - | - |
| Compulsorily convertible preference shares of Rs. 10/- each | - | - | - | - |
| Optionally convertible preference shares of Rs. 10/- each | - | - | - | - |
| Redeemable preference shares of Rs. 10/- each | - | - | - | - |
| TOTAL | 103600 | 1036000.00 | 103600 | 1036000.00 |
| c SUBSCRIBED & FULLY PAID UP CAPITAL | | | | |
| Equity shares of Rs. 10/- each with voting rights | 103600 | 1036000.00 | 103600 | 1036000.00 |
| Equity shares of Rs. 10/- each with differential voting rights | - | - | - | - |
| Compulsorily convertible preference shares of Rs. 10/- each | - | - | - | - |
| Optionally convertible preference shares of Rs. 10/- each | - | - | - | - |
| Redeemable preference shares of Rs. 10/- each | - | - | - | - |
| TOTAL | 103600 | 1036000.00 | 103600 | 1036000.00 |

B (i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

| Particulars | Opening Balance | Fresh issue | Bonus | ESOP | Conversion | Buy back | Other changes (give details) | Closing Balance |
|----------------------------------|-----------------|-------------|-------|------|------------|----------|---------------------------------|-----------------|
| Equity shares with voting rights | | | | | | | | |
| Year ended 31 March, 2021 | | | | | | | | |
| - Number of shares | 103600 | - | - | - | - | - | - | 103600 |
| - Amount Rs. | 1036000.00 | - | - | - | - | - | - | 1036000.00 |
| Year ended 31 March, 2020 | | | | | | | | |
| - Number of shares | 103600 | - | - | - | - | - | - | 103600 |
| - Amount Rs. | 1036000.00 | - | - | - | - | - | - | 1036000.00 |

- (i) 103600 (Previous Year 103600) Equity Shares with Voting rights of Rs. 10/- each called & fully paid up
(ii) 103600 (Previous Year 103600) Equity Shares with Voting rights of Rs. 10/- each called & fully paid up
(iii) Details of shares held by the holding company, the ultimate holding company, their subsidiaries and associates:

| Particulars | Equity shares with voting rights | Equity shares with differential voting rights | Compulsorily convertible preference shares | Optionally convertible preference shares | Redeemable preference shares |
|--|----------------------------------|---|--|--|------------------------------|
| Number of shares | | | | | |
| As at 31 March, 2021 | | | | | |
| the holding company | - | - | - | - | - |
| the ultimate holding company | - | - | - | - | - |
| Subsidiaries of the holding company | - | - | - | - | - |
| Associates of the holding company | - | - | - | - | - |
| Subsidiaries of the ultimate holding company | - | - | - | - | - |
| Associates of the ultimate holding company | - | - | - | - | - |
| As at 31 March, 2020 | | | | | |
| the holding company | - | - | - | - | - |
| the ultimate holding company | - | - | - | - | - |
| Subsidiaries of the holding company | - | - | - | - | - |
| Associates of the holding company | - | - | - | - | - |
| Subsidiaries of the ultimate holding company | - | - | - | - | - |
| Associates of the ultimate holding company | - | - | - | - | - |

(iv) Details of shares held by each shareholder holding more than 5% shares:

| Class of shares / Name of shareholder | As at 31 March, 2021 | | As at 31 March, 2020 | |
|---------------------------------------|-----------------------|-----------------------------------|-----------------------|-----------------------------------|
| | Number of shares held | % holding in that class of shares | Number of shares held | % holding in that class of shares |
| | | | | |

As Per Annexure Attached

- (v) As at 31 March, 2021 No shares (As at 31 March, 2020 No shares) were reserved for issuance as follows: Nil
(vi) Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received Nil
(vii) Details of calls unpaid Nil
(viii) Details of forfeited shares Nil



RODEC PHARMACEUTICALS PRIVATE LIMITED

Note No. - 2

RESERVES & SURPLUS

Share Premium Account

Opening Balance
Add ; Share Premium received during the Year
Closing Balance

As at 31 March, 2021

As at 31 March, 2020

| | | |
|--|---------------------|--------------------|
| Opening Balance | 9324000.00 | 9324000.00 |
| Add ; Share Premium received during the Year | - | - |
| Closing Balance | 9324000.00 | 9324000.00 |
| Profit & Loss Account | | |
| Opening Balance | 73195343.77 | 54871130.25 |
| Add ; Net Profit / (Net Loss) for the year | 34145029.14 | 18324213.52 |
| Closing Balance | 107340372.91 | 73195343.77 |
| TOTAL Rs. | 116664372.91 | 82519343.77 |

NON CURRENT LIABILITIES

Note No. - 3

LONG TERM BORROWINGS

Secured Loans from Banks & Financial Institutions

ICICI Bank
(Hypothecation of Motor Car)
ICICI Bank
(Hypothecation of Motor Car)
HDFC Bank
(Hypothecation of Motor Car)
AXIS Bank
(Hypothecation of Motor Car)
AXIS Bank
(WCTL under GECL)

Unsecured Loans from Directors, Shareholders & others

(List enclosed)

| | Current Maturities | Non Current Maturities | Current Maturities | Non Current Maturities |
|--|--------------------|------------------------|--------------------|------------------------|
| ICICI Bank (Hypothecation of Motor Car) | 399702.10 | - | 655588.40 | 399702.10 |
| ICICI Bank (Hypothecation of Motor Car) | - | - | 257918.30 | - |
| HDFC Bank (Hypothecation of Motor Car) | 240001.55 | 550903.71 | 219091.50 | 790905.26 |
| AXIS Bank (Hypothecation of Motor Car) | 906644.00 | 3966170.00 | - | - |
| AXIS Bank (WCTL under GECL) | 32877.00 | 8000000.00 | - | - |
| Unsecured Loans from Directors, Shareholders & others (List enclosed) | - | 5767420.00 | - | 2814089.00 |
| TOTAL Rs. | 1579224.65 | 18284493.71 | 1132598.20 | 4004696.36 |

Note No. - 4

OTHER LONG TERM LIABILITIES

Security Deposits

| | | |
|-------------------|-------------------|-------------------|
| Security Deposits | 3700000.00 | 4100000.00 |
| TOTAL Rs. | 3700000.00 | 4100000.00 |

Note No. - 5

LONG TERM PROVISIONS

No Provision for gratuity is made as there is No Liability for the same. The same is dealt on cash Basis.

CURRENT LIABILITIES

Note No. - 6

SHORT TERM BORROWINGS

Loans repayable on Demand

From Banks

Secured

Axis Bank - Cash Credit

(Hypothecation of Stock and Book Debts)

19485826.80

40679958.63

| | | |
|------------------|--------------------|--------------------|
| TOTAL Rs. | 19485826.80 | 40679958.63 |
|------------------|--------------------|--------------------|

Note No. - 7

TRADE PAYABLES

Trade Payables (List Enclosed)

32873546.93

24936187.48

| | | |
|------------------|--------------------|--------------------|
| TOTAL Rs. | 32873546.93 | 24936187.48 |
|------------------|--------------------|--------------------|

Balances of Trade Payables are subject to confirmation

Note No. - 8

OTHER CURRENT LIABILITIES

Long Term Borrowing Payable with in one year (Note No.3)
Salary Payable
Audit Fee Payable
Incentive Payable
Directors' Salary Payable
EPF Payable (Paid on 13.04.2021)
ESI Payable (Paid on 13.04.2021)
Telephone Charges Payable
Salesman Salary & Other Expenses Payable
GST Payable (Paid on 19.04.2021)
TDS Payable (Paid on 06.04.2021, 07.04.2021, 29.04.2021, 30.04.2021, 13.05.2021 & 26.05.2021)
Electricity Charges Payable
Advance from Customers (List enclosed)

| | | |
|---|--------------------|--------------------|
| Long Term Borrowing Payable with in one year (Note No.3) | 1579224.65 | 1132598.20 |
| Salary Payable | 1314168.00 | 1192862.00 |
| Audit Fee Payable | 358500.00 | 258500.00 |
| Incentive Payable | 6628436.00 | 437023.00 |
| Directors' Salary Payable | 1023880.35 | 205746.08 |
| EPF Payable (Paid on 13.04.2021) | 705801.00 | 655200.00 |
| ESI Payable (Paid on 13.04.2021) | 119456.00 | 109494.00 |
| Telephone Charges Payable | 2003.75 | 4777.35 |
| Salesman Salary & Other Expenses Payable | 12849740.54 | 11957233.54 |
| GST Payable (Paid on 19.04.2021) | 1367680.48 | 791823.00 |
| TDS Payable (Paid on 06.04.2021, 07.04.2021, 29.04.2021, 30.04.2021, 13.05.2021 & 26.05.2021) | 1142440.40 | 644236.00 |
| Electricity Charges Payable | 27115.00 | - |
| Advance from Customers (List enclosed) | 49969.87 | 32300.28 |
| TOTAL Rs. | 27168416.04 | 17421793.45 |

Balances of Advance from Customers are subject to confirmation

Note No. - 9

SHORT TERM PROVISIONS

Provision For Income Tax

12000000.00

6775000.00

| | | |
|------------------|--------------------|-------------------|
| TOTAL Rs. | 12000000.00 | 6775000.00 |
|------------------|--------------------|-------------------|



| S.NO. | PARTICULARS | GROSS BLOCK | | DELETIONS | | AS AT | | DEPRECIATION | | UP TO | | NET BLOCK | |
|---------------------------------|--|---------------------|-------------|-----------|---------------------|---------------------|-----------------|--------------|---------------------|---------------------|---------------------|-------------|------------|
| | | AS AT 01.04.2020 | ADDITIONS | DELETIONS | AS AT 31.03.2021 | UP TO 31.03.2020 | FOR THE YEAR | DEDUCTION | UP TO 31.03.2021 | AS AT 31.03.2021 | AS AT 31.03.2020 | | |
| 1 | Plot Situated at C-2, Meerut Road, Gzb | - | 64354431.00 | - | 64354431.00 | - | - | - | - | - | - | 64354431.00 | - |
| 2 | Land | 2430000.00 | - | - | 2430000.00 | - | - | - | - | - | - | 2430000.00 | 2430000.00 |
| 3 | Furniture & Fixtures | 1900001.00 | - | - | 1900001.00 | 1577840.13 | 84708.82 | - | 1662548.75 | - | - | 237452.25 | 322160.87 |
| 4 | Computer | 1457757.85 | 158425.43 | - | 1616183.28 | 1288480.47 | 101043.28 | - | 1389523.75 | - | - | 226659.53 | 169277.38 |
| 5 | Motor Car | 8721807.61 | 6619761.08 | - | 15341568.69 | 5182988.81 | 1858482.28 | - | 7041471.09 | - | - | 8300097.60 | 3538818.80 |
| 6 | Scooters | 51300.00 | - | 51300.00 | - | 45717.16 | - | 45717.16 | - | - | - | - | 5582.84 |
| 7 | Air Conditioner | 783734.00 | - | - | 783734.00 | 657994.62 | 41597.08 | - | 699591.70 | - | - | 84142.30 | 125739.38 |
| 8 | Office Equipment | 1041678.00 | 27455.94 | - | 1069133.94 | 995480.04 | 11097.04 | - | 1006577.08 | - | - | 62556.86 | 46197.96 |
| 9 | Mobile | 572948.59 | 197722.62 | - | 770671.21 | 419545.59 | 106908.89 | - | 526454.48 | - | - | 244216.73 | 153403.00 |
| 10 | Cycle | 39736.50 | - | - | 39736.50 | 34233.46 | 1236.53 | - | 35469.99 | - | - | 4266.51 | 5503.04 |
| 11 | Weighing Machine | 7000.00 | - | - | 7000.00 | 6059.63 | 205.68 | - | 6265.31 | - | - | 734.69 | 940.37 |
| 12 | Generator | 354250.00 | - | - | 354250.00 | 294826.33 | 15506.84 | - | 310333.17 | - | - | 43916.83 | 59423.67 |
| 13 | Tempo | 350000.00 | - | - | 350000.00 | 256694.35 | 24153.83 | - | 280848.18 | - | - | 69151.82 | 93305.65 |
| CAPITAL WORK IN PROGRESS | | | | | | | | | | | | | |
| 14 | Building | - | 51958.22 | - | 51958.22 | - | - | - | - | - | - | 51958.22 | - |
| TOTAL Rs. | | 17710213.55 | 71409754.29 | 51300.00 | 89068667.84 | 10759860.59 | 2244940.07 | 45717.16 | 12959083.50 | 76109584.34 | 6950352.96 | 7586302.39 | |
| PREVIOUS YEAR Rs. | | 16512300.72 | 1197912.83 | - | 17710213.55 | 8925998.33 | 1833862.26 | - | 10759860.59 | 6950352.96 | 7586302.39 | | |



RODEC PHARMACEUTICALS PRIVATE LIMITED

NON CURRENT ASSETS

As at 31 March, 2021

As at 31 March, 2020

Note No. - 11

DEFERRED TAX ASSETS (NET)

Deferred tax is accounted for by computing the tax effect of timing difference of Depreciation that arises during the year and reverse in subsequent year.
During the year, deferred tax liability of Rs.116891.00 has been recognised and dedited in the statement of Profit & Loss account.

| | | |
|--|------------------|------------------|
| Opening Balance | 711062.00 | 834258.00 |
| Deferred Tax Asset (Liability) during the Year | 116891.00 | -123196.00 |
| TOTAL Rs. | 827953.00 | 711062.00 |

Note No. - 12

LONG TERM LOANS & ADVANCES

| | | |
|--|--------------------|------------------|
| Security Deposit with Mobile | 3000.00 | 3000.00 |
| Security Deposit Against Rent | 40000.00 | 40000.00 |
| Security Deposit with Electricity Department | 30000.00 | 30000.00 |
| Security Deposit with Rodec Helathcare (P) Ltd | 10000000.00 | - |
| Life Insurance Corporation of India from Pension and Group Schemes | 448012.61 | 484826.78 |
| TOTAL Rs. | 10321012.61 | 537826.78 |

CURRENT ASSETS

Note No. - 13

INVENTORIES

(Taken, Valued & Verified by the Management of The Company)

| | | |
|------------------|--------------------|--------------------|
| Finished Goods | 14590862.00 | 11864522.00 |
| TOTAL Rs. | 14590862.00 | 11864522.00 |

Finished Goods are valued at Cost Price or Market Price, which ever is lower.

Note No. - 14

TRADE RECEIVABLES (To the extent considered good)

Trade receivables outstanding for a period exceeding six months from the date they were due for payment

| | | |
|--|--------------------|--------------------|
| Secured, considered good | - | - |
| Unsecured, considered good | 3389581.40 | 8285126.16 |
| Doubtful | - | - |
| (List enclosed) | 3389581.40 | 8285126.16 |
| Less: Provision for doubtful trade receivables | - | 3389581.40 |
| | | 8285126.16 |
| Other Trade receivables | | |
| Secured, considered good | - | - |
| Unsecured, considered good | 72285810.27 | 64579824.80 |
| Doubtful | - | - |
| (List enclosed) | 72285810.27 | 64579824.80 |
| Less: Provision for doubtful trade receivables | - | 72285810.27 |
| | | 64579824.80 |
| TOTAL Rs. | 75675391.67 | 72864950.96 |

Balances of trade receivables are subject to confirmation

Note No. - 15

CASH & CASH EQUIVALENTS

| | | |
|--------------------------------------|------------------|-------------------|
| Cash in Hand | 115337.38 | 1616936.34 |
| Fixed Deposit against Bank Guarantee | 317100.00 | - |
| Axis Bank, C/A - 8168 | 39667.00 | 63637.00 |
| TOTAL Rs. | 472104.38 | 1680573.34 |

Note No. - 16

SHORT TERM LOANS & ADVANCES

| | | |
|---------------------------------------|--------------------|--------------------|
| Sundry/Other Advances (List enclosed) | 38470278.48 | 73502577.57 |
| Advance to Staff & Directors | 1763735.00 | 4872985.00 |
| Income Tax Refundable | 931293.00 | 2102650.00 |
| Advance Income Tax, TDS & TCS | 10095887.53 | 4888595.00 |
| GST Recoverable | 1115913.38 | 921209.08 |
| Prepaid Expenses | 195901.00 | 92935.00 |
| Tender Fee Refundable | - | 20000.00 |
| Deposit with Labour Court | 442740.00 | 442740.00 |
| TOTAL Rs. | 53015748.39 | 86843691.65 |

Balances of Sundry/Other Advances are subject to confirmation

In the opinion of the board of directors, the aggregate value of current assets on realization will not be less than amount at which they are stated in the balance sheet.



RODEC PHARMACEUTICALS PRIVATE LIMITED

CONTINUING OPERATIONS

| Note No. - 17 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|--------------------------------|--|--|
| REVENUE FROM OPERATIONS | | |
| Sales | 457451411.28 | 327345935.58 |
| TOTAL Rs. | <u>457451411.28</u> | <u>327345935.58</u> |

| Note No. - 18 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|-----------------------------------|--|--|
| PURCHASE OF STOCK IN TRADE | | |
| Purchases | 191474233.31 | 138989933.85 |
| TOTAL Rs. | <u>191474233.31</u> | <u>138989933.85</u> |

| Note No. - 19 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|---|--|--|
| CHANGE IN INVENTORIES OF FINISHED GOODS, WORK IN PROGRESS & STOCK IN TRADE | | |
| Opening Stock :- | | |
| Finished Goods | 11864522.00 | 7684509.76 |
| | 11864522.00 | 7684509.76 |
| Closing Stock :- | | |
| Finished Goods | 14590862.00 | 11864522.00 |
| | 14590862.00 | 11864522.00 |
| Increase / Decrease in Finished Goods | <u>-2726340.00</u> | <u>-4180012.24</u> |

| Note No. - 20 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|----------------------------------|--|--|
| EMPLOYEE BENEFIT EXPENSES | | |
| Salaries to Staff & Salesmen | 91444843.00 | 83080333.00 |
| Directors' Salary | 9600000.00 | 7950000.00 |
| Employer's Contribution to P.F | 4002834.00 | 3430815.00 |
| Employer's Contribution to E.S.I | 1064082.00 | 1092295.00 |
| Donus & Incentive to Staff | 11297640.00 | 2511001.00 |
| Gratuity (Paid) | 537486.00 | 71827.00 |
| Staff Welfare | 300696.46 | 264467.61 |
| TOTAL Rs. | <u>118247581.46</u> | <u>98430738.61</u> |

| Note No. - 21 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|--|--|--|
| OTHER EXPENSES | | |
| Freight Inward | 1385942.56 | 754533.00 |
| ADMINISTRATIVE & SELLING EXPENSES | | |
| Printing & Stationery | 792914.00 | 686512.00 |
| Telephone & Mobile Charges | 1532229.19 | 1737846.89 |
| Travelling & Conveyance | 26033024.20 | 29484195.66 |
| Postage, Courier & Internet | 210790.10 | 229859.50 |
| Rent, Rates & Taxes | 2432080.46 | 1823081.00 |
| Electricity & Generator Charges | 661334.89 | 435963.65 |
| Legal & Professional Charges | 2781239.00 | 811716.00 |
| Fees & Subscription | 142051.44 | 101762.65 |
| Marketing Expenses | 1661797.73 | 894656.42 |
| Repair & Maintenance | 1142023.11 | 883386.23 |
| Miscellaneous Expenses | 71806.93 | 3340.28 |
| Charity & Donation | 266000.00 | 276000.00 |
| Auditor's Remuneration | 100000.00 | 100000.00 |
| Insurance | 697005.55 | 564405.04 |
| Advertisement | 71226.00 | 173181.00 |
| Expiry & Brekage | 5209234.12 | 3208402.04 |
| Rebate & Discount | 2822961.85 | 1587328.09 |
| Freight Outward | 4834460.92 | 3947628.13 |
| Sales Promotion | 32952762.85 | 19759784.92 |
| Commission (Paid) | 17582141.08 | 943896.20 |
| Entry Tax, Sales Tax & GST (Paid) | 145030.00 | 186382.00 |
| TOTAL Rs. | <u>103528055.98</u> | <u>68593860.70</u> |

| Note No. - 22 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|-------------------------------|--|--|
| FINANCE COSTS | | |
| Bank Charges & Interest | 2420252.23 | 4115605.20 |
| Interest on Security Deposits | 290000.00 | 290000.00 |
| Finance Charges | 279291.20 | 268849.66 |
| Interest on Unsecured Loans | 798146.00 | 798649.00 |
| TOTAL Rs. | <u>3787689.43</u> | <u>5473103.86</u> |

| Note No. - 23 | For The Year Ended 31st March, 2021 | For The Year Ended 31st March, 2020 |
|--------------------------------|--|--|
| OTHER INCOME | | |
| Profit on Sale of Fixed Assets | 3417.16 | 186440.00 |
| Interest on Income Tax Refund | 84104.00 | - |
| Interest (Received) | 5194926.95 | 6926514.98 |
| TOTAL Rs. | <u>5282448.11</u> | <u>7112954.98</u> |



RODEC PHARMACEUTICALS PRIVATE LIMITED
CIN: U24233DL1997PTC090729

**SIGNIFICANT ACCOUNTING POLICIES & NOTES ON FINANCIAL STATEMENTS FOR THE
YEAR ENDED 31st MARCH, 2021**

Note No. : 24

A. Significant Accounting Policies

1. Basis of accounting:-

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on accrual basis.

2. Revenue Recognition :-

Expenses and Income considered payable and receivable respectively are accounted for on accrual basis except discount claims, rebates and retirement benefits which cannot be determined with certainty during the year.

3. Fixed Assets :-

Fixed assets are stated at their original cost of acquisition including taxes, freight and other incidental expenses related to acquisition and installation of the concerned assets less depreciation till date.

4. Depreciation :-

Depreciation on Fixed Assets is provided to the extent of depreciable amount on the Written down Value (WDV) Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.

5. Inventories :-

Inventories are valued as under:-

Inventories : Lower of cost or net realizable value



6. Retirement Benefits:-

The gratuity, leave encashment and retirement benefits are accounted for as and when the liability for it becomes due for payment.

7. Taxes on Income:-

Provision for current tax is made on the basis of estimated taxable income for the current accounting year in accordance with the Income Tax Act, 1961.

8. Provisions, Contingent Liabilities and Contingent Assets:- (As-29)

Provisions are recognized only when there is a present obligation as a result of past events and when a reliable estimate of the amount of the obligation can be made.

Contingent Liabilities is disclosed in Notes to the account for:-

- (i) Possible obligations which will be confirmed only by future events not wholly within the control of the company or
- (ii) Present Obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are not recognized in the financial statement since this may result in the recognition of the income that may never be realized.

General:

Except wherever stated, accounting policies are consistent with the generally accepted accounting principles and have been consistently applied.

(B) Notes on Financial Statements

1. The SSI status of the creditors is not known to the Company; hence the information is not given.
2. Previous years' figures have been regrouped/recast to make them comparable with the current year.
3. Trade receivables, Trade payables, Advance from Customers, Security Deposits (Received), Loans & Advances and Unsecured Loans GST recoverable/Payable, Purchases as well as Gross Turnover have been taken at their book value subject to confirmation and reconciliation.
4. Payments to Auditors:

| Auditors Remuneration | 2020-21 | 2019-2020 |
|------------------------------|------------------|------------------|
| Audit Fees | 60000.00 | 60000.00 |
| Tax Audit Fees | 40000.00 | 40000.00 |
| Company Law Matters | Nil | Nil |
| GST | Nil | Nil |
| Total | 100000.00 | 100000.00 |



5. Loans and Advances are considered good in respect of which company does not hold any security other than the personal guarantee of persons.

6. Related Party disclosure

(I) Key Management Personnel

1. Mukesh Kumar Gupta
2. Smt. Chhaya Gupta
3. Ms. Shubhangi Gupta

(II) Relative of Key Management Personnel

1. Rodec Healthcare Private Limited
2. Ms.Nupur Gupta

7. Value of Imports

Raw Material Nil
Finished Goods Nil

8. Expenditure in Foreign Currency Nil

9. Earning in Foreign Exchange Nil

10. All assets and liabilities are presented as Current or Non-current as per criteria set out in Revised Schedule VI to the Company's Act, 1956 Notified by the Ministry of Corporate affairs vide Notification No. SO447(E) Dated 28th February, 2011 and SO653(E) Dated 30th March, 2011. Based on the nature of operation of the company and realization from the trade receivable, the company has ascertained its operating cycle of less than 12 months. Accordingly 12 months period has been considered for the purpose of Current /Non-current classification of assets & liabilities.

In terms of Our Separate Audit Report of Even Date Attached.

For Rishi Kapoor & Company
Chartered Accountants
FRNo 0066615C



A handwritten signature in blue ink, appearing to be "Rishi Kapoor".

(Rishi Kapoor)
Partner
M.No.075483

A handwritten signature in blue ink, appearing to be "Mukesh Kumar Gupta".

(Mukesh Kumar Gupta)
Director
DIN: 00555175

A handwritten signature in blue ink, appearing to be "Chhaya Gupta".

(Chhaya Gupta)
Director
DIN: 00560474

Place : Ghaziabad
Date : 02.09.2021